Transport Protein Assays Kit Market Size, Share, Opportunities, And Trends By Product (Efflux Transporter Kits, Uptake Transporter Kits, Reagents, Consumables), By Application (Drug Delivery And Development, Disease Diagnosis, Phagocytosis, Cell Signaling, Cell Transport Studies, Cell Membrane Studies), By End- User (Pharmaceutical Companies, Biotechnological Companies, Hospitals, Diagnostic Laboratories, Academic And Research Institutes, Contract Research Organization), And By Geography - Forecasts From 2024 To 2029

The transport protein assay kit market is projected to show steady growth during the forecast period.

Transport protein assay kits are used for quantifying the capacity of transport proteins to facilitate the transportation of substances across biological membranes. Such kits are utilized in the field of drug discovery and development to investigate the relationship between drug compounds and transport proteins. Three categories of transport protein assay kits include Efflux Transporter Kits, Uptake Transporter Kits, and Consumables. The rise in chronic diseases, research and development activities, coupled with investment in pharmaceuticals are driving the transport protein assay kit market growth.

Market Drivers:

• The rising chronic disease prevalence is driving the transport protein assay kit market growth.

The rapid increase in the prevalence of chronic diseases like cancer, cardiovascular diseases (CVDs), and diabetes presents a significant obstacle to public health and a complex issue. Such a rise in chronic diseases and associated mortality rates is projected to drive a substantial surge in the demand for protein assays across various fields, including drug discovery and development, disease screening, and diagnosis. According to the World Health Organization (WHO) report September 2023 report, noncommunicable diseases (NCDs) claim the lives of 41 million individuals annually, representing 74% of all global fatalities. The majority of noncommunicable deaths are attributed to cardiovascular diseases, with 17.9 million deaths per year, followed by cancers (9.3 million), chronic respiratory diseases (4.1 million), and diabetes (2.0 million), which includes deaths from kidney disease related to diabetes. According to the same source February 2024 report, in the year 2022, approximately 20 million individuals were diagnosed with cancer, resulting in 9.7 million fatalities.

• Growing research and development is propelling the transport protein assay kit market growth.

The field of transport protein assays is presently experiencing exciting advancements, driven by the increasing demand for efficient, reliable, and versatile tools to investigate the crucial components of cells. Research & Development drive the expansion of the market with novel examinations that enhance detection, and comprehension results in specialized kits. According to the National Library of Medicine published article in February 2023, a study centered on creating a unique test was conducted to examine the function of the ABCB4 transport protein, crucial in the process of bile formation in the liver. The anticipated results involved the introduction of a novel testing approach that precisely evaluates ABCB4 activity, which could potentially assist in drug development and enhance comprehension of liver diseases.

• Investment in pharmaceuticals enhances the transport protein assay kit market growth.

The rise in chronic diseases worldwide is fueling the growth in funding for pharmaceutical and biological research and development projects. Such increased funding in pharmaceutical research and development has positively impacted transporter protein assay kits market demand as they play a crucial role in enhancing drug development, forecasting drug reactions, and tailoring dosage, thereby ultimately resulting in the creation of safer and more efficient medications. According to a press release by AstraZeneca in December 2023, the company invested $1.2 billion in acquiring Gracell, which specializes in cell therapy. The strategic move is aimed at transforming the landscape of cancer and autoimmune disease treatments. According to Merck's report, in 2023, the company’s investment in research and development reached $30 billion. The emphasis is on the development of new pharmaceuticals, the enhancement of existing drugs, and the advancement of fundamental research to gain a better understanding of diseases and biological mechanisms.

North America is expected to grow significantly.

North America is projected to account for a significant share of the transport protein assay kit market due to investment and initiatives in the field of biotechnology. In September 2022, the Department of Health and Human Services (HHS) launched a National Biodefense Strategy to advance medical advancements. The initiatives include developing innovative therapies and remedies, as well as enhancing diagnostic tools and personalized healthcare. The objective was to lessen the overall disease impact on the nation by enhancing prevention, detection, and treatment. As per the initiative (HHS) allocated a substantial amount of $40 million towards enhancing biomanufacturing capabilities for vital medications such as antibiotics and active ingredients.  Likewise, in March 2023, the Government of Canada allocated $23 million (SIF) to support Ontario's Edesa Biotech in expediting the phase III trials of EB05, a monoclonal antibody therapy for COVID- Acute Respiratory Distress Syndrome (ARDS). The investment strengthens Canada's life sciences industry and enhances its readiness to combat pandemics.

Market Restraints:

• High costs will restrain the transport protein assay kit market growth.

When it comes to their operation and handling the cost of these kits can be high due to the need for specialized reagents which makes them less accessible, particularly for smaller institutions. Such high costs can act as an obstacle to the market growth.

Key developments:

• In October 2023: Molecular Devices recently introduced CellXpress.ai, an automated cell culture system created to enhance the speed of drug discovery. The system, powered by AI, handles feeding, passaging, and imaging of cells, allowing scientists more time and guaranteeing dependable outcomes.
• In July 2023: QIAGEN, a renowned company in the life sciences sector,  unveiled a new collaboration with Niba Labs to provide tailored digital PCR (dPCR) assay design services to biopharmaceutical clients. The collaboration aimed at advancing the progress of cell and gene therapies.

Company Products:

• Pierce BCA protein assay kits: The Pierce BCA Protein Assay Kit offered by ThermoFisher Scientific is a precise and reliable protein assay that is compatible with detergents. It is designed to accurately determine the concentration of proteins in various sample types commonly encountered in protein research.
• BCA protein assay kit: The Novagen® BCA Protein Assay Kit serves as a valuable instrument for quantifying protein concentration in a solution. Its design is tailored to cater to the needs of research and laboratory settings.

Segmentation

• By Product
  • Efflux transporter kits
  • Uptake transporter kits
  • Reagents
  • Consumables
• By Application
  • Drug Delivery and Development
  • Disease Diagnosis
  • Phagocytosis
  • Cell Signaling
  • Cell Transport Studies
  • Cell Membrane Studies
• By End- User
  • Pharmaceutical Companies
  • Biotechnological Companies
  • Hospitals
  • Diagnostic Laboratories
  • Academic And Research Institutes
  • Contract Research Organization
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Taiwan
    • Thailand
    • Indonesia
    • Others